Liposome-containing composition for cosmetics, and cosmetics

Abstract

The present invention provides a liposome-containing composition for cosmetics that stably contains γ-aminobutyric acid and fine liposomes having a single lamellar structure, and a cosmetic composition using the above-mentioned liposome-containing composition for cosmetics. [Solution] A liposome-containing composition for cosmetics containing liposomes and water, wherein the liposomes contain compound E, which is at least one selected from the group consisting of γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, fatty acid phytosteryl, and sphingoid bases, and the liposomes contain liposomes having a single lamellar structure and an average particle diameter of 100 nm to 500 nm, and a cosmetic made using the above liposome-containing composition for cosmetics.

Description

Technical Field

[0001] The present disclosure relates to a liposome-containing composition for cosmetics and cosmetics.

Background Art

[0002] A liposome is a closed vesicle formed by a lipid bilayer containing lipids such as lecithin, and has an aqueous phase (inner aqueous phase) in the space inside the closed vesicle. Also, usually, liposomes exist in a state dispersed in an aqueous solution (outer aqueous phase) outside the closed vesicle. Various encapsulating components can be incorporated into liposomes, and as encapsulating components, various liposome-containing compositions for cosmetics encapsulating various cosmetic components, medicinal components, etc. have been proposed.

[0003] Patent Document 1 proposes a liposome-containing composition for cosmetics, which contains liposomes and a dispersion medium for dispersing the liposomes, wherein the liposomes contain stearyl glycyrrhetinate, polyoxyethylene phytosterol, and one or more compounds A selected from the group consisting of cholesterol and phytosterols other than the above polyoxyethylene phytosterol, and lecithin, and have a single lamellar structure.

[0004] γ-Aminobutyric acid (GABA: Gamma-aminobutyric acid) is known to contribute to various effects such as an anti-skin aging effect due to a skin vasodilation effect, a collagen production promoting effect, a hair growth effect, and a whitening effect. Also, it is known from the catalog information of raw material manufacturers that γ-aminobutyric acid has a proliferation effect on epidermal cells and a promoting effect on the production of hyaluronic acid.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Summary of the Invention

[0006] There is a demand for incorporating gamma-aminobutyric acid (γ-aminobutyric acid) into cosmetics, given its various effects. When applying cosmetics containing γ-aminobutyric acid to the skin, there is a need for a method to deliver γ-aminobutyric acid more efficiently into the skin. One such method is to encapsulate γ-aminobutyric acid in liposomes.

[0007] Liposomes consist of a closed vesicle formed by a lipid bilayer and an encapsulated substance contained within the closed vesicle. Their morphology includes liposomes with a single-lamellar structure (also called monolayer vesicles) where the lipid bilayer is a single layer, and liposomes with a multi-lamellar structure where the lipid bilayer is a multilayer structure. From the viewpoint of being able to encapsulate a larger amount of the water-soluble component γ-aminobutyric acid and having excellent penetration into the skin, it is desirable for liposomes to have a single-lamellar structure and have a fine average particle size.

[0008] For example, Patent Document 1 describes a liposome-containing composition for cosmetics that includes liposomes having a single-lamellar structure with a specific configuration. However, it was found that when γ-aminobutyric acid was added when forming the liposomes having a single-lamellar structure as described in Patent Document 1, the liposome formation ability decreased, resulting in unstable liposomes with an undesirable increase in average particle size.

[0009] This disclosure has been made in view of the circumstances described above. One embodiment of this disclosure aims to solve the problem of providing a liposome-containing composition for cosmetics that stably contains fine liposomes having a single lamellar structure and containing γ-aminobutyric acid. In this disclosure, "fine liposomes" means that the average particle size of the liposomes is 500 nm or less. Another embodiment of this disclosure aims to solve the problem of providing a cosmetic product using the above-mentioned liposome-containing composition for cosmetics. [Means for solving the problem]

[0010] This disclosure includes the following aspects: [1] A liposome-containing composition for cosmetic use, comprising liposomes and water, wherein the liposomes comprise compound E, which is at least one selected from the group consisting of γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, fatty acid phytosteryls, and sphingoid bases, and further comprising liposomes having a single lamellar structure and an average particle diameter of 100 nm to 500 nm. [2] The liposome-containing cosmetic composition according to [1], wherein the ratio of the content of γ-aminobutyric acid to the content of compound E is 0.4 to 1000 by mass. [3] A liposome-containing cosmetic composition according to [1] or [2], wherein the ratio of the content of γ-aminobutyric acid to the total content of polyoxyethylene phytosterol, cholesterol, and lecithin is 0.05 to 20.0 by mass. [4] A liposome-containing cosmetic composition according to any one of [1] to [3], further comprising ergothioneine. [5] A cosmetic product comprising a liposome-containing composition for cosmetic products described in any one of [1] to [4]. [Effects of the Invention]

[0011] According to one embodiment of the present disclosure, a liposome-containing composition can be provided that stably contains fine liposomes having a single lamellar structure and containing γ-aminobutyric acid. Furthermore, according to another embodiment of this disclosure, a cosmetic product can be provided that uses the above-mentioned liposome-containing composition for cosmetics. [Modes for carrying out the invention]

[0012] The following describes in detail an example of an embodiment of the liposome-containing composition and cosmetic product relating to this disclosure. However, the liposome-containing composition and cosmetic product relating to this disclosure are not limited to the embodiments described below, and can be implemented with appropriate modifications within the scope of the purpose of this disclosure.

[0013] In this disclosure, the numerical range indicated using "~" includes the numbers before and after "~" as the minimum and maximum values, respectively. In numerical ranges described in stages within this disclosure, the upper or lower limit of one numerical range may be replaced with the upper or lower limit of another numerical range described in stages. Furthermore, in numerical ranges described within this disclosure, the upper or lower limit of that range may be replaced with the values ​​shown in the examples. In this disclosure, each component may contain multiple types of the corresponding compound. If multiple substances corresponding to each component are present in the composition, the content of each component means the total content of those multiple substances present in the composition unless otherwise specified. In this disclosure, a combination of two or more preferred embodiments is a more preferred embodiment. In this disclosure, "mass%" and "weight%" are synonymous, and "parts by mass" and "parts by weight" are synonymous. In this disclosure, "cholesterol" is a general term for sterols found in animals, and "phytosterol" is a general term for sterols found in plants. In this disclosure, "water-soluble" means that the solubility in 100g of water at a liquid temperature of 22°C and pH 7.0 is 0.1g or more.

[0014] <<Liposome-containing composition for cosmetic use>> The liposome-containing composition for cosmetics according to the present disclosure contains liposomes and water, and the liposomes contain γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, and at least one compound E selected from the group consisting of fatty acid phytosteryl and sphingoid base (hereinafter simply referred to as "compound E"), and contains liposomes having a single lamellar structure and an average particle size of 100 nm to 500 nm (hereinafter also referred to as "specific liposomes").

[0015] Incidentally, hereinafter, γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, and compound E contained in the specific liposomes may be referred to as component A, component B, component C, component D, and component E, respectively.

[0016] With the above configuration, the liposome-containing composition for cosmetics according to the present disclosure contains γ-aminobutyric acid and stably contains fine liposomes having a single lamellar structure.

[0017] The liposome-containing composition for cosmetics according to the present disclosure contains, as components constituting the liposomes, in addition to each of polyoxyethylene phytosterol (component B), cholesterol (component C), and lecithin (component D), at least one compound E (component E) selected from the group consisting of fatty acid phytosteryl and sphingoid base. As a result, it has been found that the liposome, while being a liposome containing γ-aminobutyric acid (component A), is stably contained in the composition as a fine liposome having a single lamellar structure and an average particle size of 100 nm to 500 nm.

[0018] Patent Document 1 does not describe liposomes corresponding to the specific liposomes.

[0019] [[ID=二十]]In the present disclosure, the specific liposomes have an average particle size of 100 nm to 500 nm from the viewpoint of increasing the encapsulation amount of γ-aminobutyric acid and excellent permeability of the liposomes to the skin.

[0020] In the present disclosure, whether a liposome-containing composition for cosmetics contains liposomes having a single lamellar structure is confirmed by the content ratio (%) of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition (hereinafter also referred to as the "single layer rate (%) of liposomes").

[0021] In the present disclosure, from the viewpoint of increasing the encapsulation amount of γ-aminobutyric acid in specific liposomes, the single layer rate (%) of liposomes is more preferably 50% or more, more preferably 70% or more, and may be 100%. More specifically, the single layer rate (%) of liposomes contained in the liposome-containing composition for cosmetics is preferably 50% to 100%, and more preferably 70% to 100%. In the present disclosure, when the single layer rate (%) of liposomes is 50% or more, it is determined that the liposome-containing composition for cosmetics stably contains liposomes having a single lamellar structure.

[0022] Note that the liposome-containing composition for cosmetics according to the present disclosure may contain liposomes having a multilamellar structure (also called multilamellar vesicles) as liposomes.

[0023] In the present disclosure, the single layer rate (%) of liposomes is determined as a percentage (%) calculated based on the count numbers obtained by observing the liposomes contained in the liposome-containing composition for cosmetics in an ice-embedded state using a transmission electron microscope (hereinafter also referred to as TEM) and counting the total number of liposomes and the total number of liposomes having a single lamellar structure contained in the liposome-containing composition for cosmetics. More specifically, first, a TEM image of the liposome-containing composition for cosmetics at a magnification of 50,000 times is obtained using TEM. For each of three randomly selected locations from the TEM image, the total number of liposomes and the total number of liposomes with a single lamellar structure within a circle with a radius of 2 μm are counted. Then, the monolayer percentage (%) is calculated based on the total number of liposomes and the total number of liposomes with a single lamellar structure. In this disclosure, "liposome monolayer percentage (%)" refers to the arithmetic mean of the three monolayer percentages (%) calculated as described above.

[0024] Furthermore, the encapsulation rate of the contents within the liposomes can be comprehensively evaluated based on the "average particle size of liposomes" and the "percentage of liposome monolayers (%)". For example, when comparing liposomes with a single-lamellar structure to liposomes with a multi-lamellar structure, if the average particle size is the same, the lipid membrane portion occupies a smaller area of ​​the total size. Therefore, liposomes with a single-lamellar structure will contain a larger amount of encapsulated material. Thus, if the "average particle size of liposomes" is equivalent, a higher percentage of monolayer liposomes indicates a higher encapsulation rate. Furthermore, when comparing liposomes with single-lamellar structures of different particle sizes, the larger the particle size, the greater the amount of encapsulated material. Therefore, if the monolayer ratio (%) of liposomes is the same, a larger "average particle size of liposomes" can be considered to indicate a higher encapsulation rate of encapsulated material in the liposomes.

[0025] In this disclosure, the specific liposomes have an average particle size of 100 nm to 500 nm, from the viewpoint of increasing the amount of γ-aminobutyric acid contained within and having excellent penetration into the skin. The average particle size of the specific liposomes is more preferably 120 nm or larger, even more preferably 140 nm or larger, and particularly preferably 170 nm or larger. Liposomes with a large particle size tend to aggregate and coalesce over time, and are prone to becoming multilamellar. Therefore, from the viewpoint of improving the time-dependent stability of liposomes and maintaining the amount of encapsulated material, the average particle size of specific liposomes is more preferably 400 nm or less, even more preferably 360 nm or more, and particularly preferably 300 nm or less. Furthermore, when the average particle size of specific liposomes is 400 nm or less, the penetration of liposomes into the skin and other tissues tends to improve. Based on the above, in one embodiment, the average particle size of the specific liposome is preferably 120 nm to 400 nm, more preferably 140 nm to 360 nm, and even more preferably 170 nm to 300 nm.

[0026] In this disclosure, the "average particle size" of liposomes refers to the volume-average particle size determined by dynamic light scattering. Examples of particle size analyzers using dynamic light scattering include the concentrated particle size analyzer FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.), NanoTrack UPA (manufactured by Nikkiso Co., Ltd.), and the dynamic light scattering particle size distribution analyzer LB-550 (manufactured by Horiba, Ltd.). The average particle size is measured by diluting the liposome-containing cosmetic composition with pure water to 10 times its mass and performing the measurement at room temperature (25°C). Furthermore, "pure water" refers to pure water obtained from ultrapure water production equipment manufactured by Merck KGaA, etc. The dynamic light scattering method described above allows for the measurement of the average particle size of liposomes contained in a liposome-containing composition for cosmetic use. While the liposome-containing composition for cosmetic use may contain some granular material other than liposomes, the average particle size determined by the above method should still be considered the average particle size of the liposomes. When determining the average particle size using the above method, filtration through a 230-mesh (pore size: 65 μm) filter may be performed before measurement.

[0027] In this disclosure, the specific liposome comprises γ-aminobutyric acid (component A), polyoxyethylene phytosterol (component B), cholesterol (component C), lecithin (component D), compound E (component E), and water.

[0028] Of the components contained in the specific liposome, γ-aminobutyric acid (component A) is preferably contained in the encapsulation of the specific liposome (i.e., the inner aqueous phase) in a state of being dissolved in water. The liposome-containing cosmetic composition according to this disclosure may also contain γ-aminobutyric acid in the aqueous solution outside the liposome (outer aqueous phase). Of the components contained in the specific liposome, polyoxyethylene phytosterol (component B), cholesterol (component C), lecithin (component D), and compound E (component E) are presumed to be contained in the lipid bilayer that constitutes the specific liposome.

[0029] (γ-aminobutyric acid: component A) The liposome-containing cosmetic composition relating to this disclosure contains gamma-aminobutyric acid (GABA) in specific liposomes. Gamma-aminobutyric acid is a water-soluble compound and is contained in at least the encapsulated substance (internal aqueous phase) of the liposomes.

[0030] Gamma-aminobutyric acid (GABA) is a substance known as an amino acid that exhibits neurotransmitter activity. GABA is known to contribute to various effects, including anti-aging effects through vasodilation of skin cells, collagen production promotion, hair growth promotion, skin whitening effects, epidermal cell proliferation, and hyaluronic acid production promotion.

[0031] For γ-aminobutyric acid, commercially available products or synthetic products may be used. Examples of commercially available gamma-aminobutyric acid include Gabacare BL98T aminobutyric acid (BLOOMAGE BIOTECHNOLOGY Corp., Ltd.) and Gamma-Aminobutyric acid - lactobacillus type (IMCD Japan LLC). γ-aminobutyric acid may be a synthetic product manufactured in accordance with known manufacturing methods. For example, γ-aminobutyric acid may be produced by adding a solution containing glutamic acid and / or glutamate salt to plants and / or plant processed products and reacting them, as described in Japanese Patent Publication No. 2013-194030, and then being produced by the enzymatic action of glutamate decarboxylase present in the plants from the glutamic acid in the solution and the glutamic acid contained in the plants and / or plant processed products.

[0032] The amount of γ-aminobutyric acid (γ-aminobutyric acid) relative to the total mass of the liposome-containing cosmetic composition can be appropriately set depending on the target application of the liposome-containing cosmetic composition. For example, the amount of γ-aminobutyric acid relative to the total mass of the liposome-containing cosmetic composition can be 0.0001% to 20% by mass.

[0033] (Polyoxyethylene phytosterol: component B) Polyoxyethylene phytosterols are (CH2CH2-O) n This is a phytosterol having an oxyethylene group represented by . In this disclosure, phytosterols include hydrogenated phytosterols (phytostanols). Specific examples of phytosterols include sitosterol, stigmasterol, fucosterol, spinasterol, brassicasterol, and their hydrogenated forms.

[0034] From the viewpoint of increasing the inclusion rate of encapsulated materials, the average number of moles of oxyethylene groups added to polyoxyethylene phytosterol is preferably 5 or more, and more preferably 10 or more. Furthermore, by setting the average number of oxyethylene groups added to polyoxyethylene phytosterol to 5 or more, the proportion of liposomes having a single lamellar structure (i.e., the monolayer ratio (%)) can be increased, thereby further improving the encapsulation rate of the liposome contents. From the viewpoint of increasing the inclusion rate of encapsulated substances, the average number of moles of oxyethylene groups added to polyoxyethylene phytosterol is preferably 5 to 30, and more preferably 10 to 20. The average number of moles of oxyethylene groups added to polyoxyethylene phytosterol can be measured by known analytical methods such as high-performance liquid chromatography (HPLC). When using commercially available products, if catalog values ​​are available, these can be referred to.

[0035] Commercially available polyoxyethylene phytosterols can be used. Commercially available polyoxyethylene phytosterols include NIKKOL® BPS-5 (average number of added moles of oxyethylene groups: 5), NIKKOL® BPS-10 (average number of added moles of oxyethylene groups: 10), NIKKOL® BPS-20 (average number of added moles of oxyethylene groups: 20), and NIKKOL® BPS-30 (average number of added moles of oxyethylene groups: 30), and NIKKOL® BPSH-25 (average number of added moles of oxyethylene groups: 25), all manufactured by Nikko Chemicals Co., Ltd. Examples include hydrogenated phytosterol ethylene oxide adducts, EMALEX® PS-5 (average number of added moles of oxyethylene groups: 5), EMALEX® PS-10 (average number of added moles of oxyethylene groups: 10), EMALEX® PS-20 (average number of added moles of oxyethylene groups: 20), and EMALEX® PS-30 (average number of added moles of oxyethylene groups: 30), and EMALEX® PS-25 (average number of added moles of oxyethylene groups: 25), all manufactured by Nippon Emulsion Co., Ltd.

[0036] The polyoxyethylene phytosterol content in the liposome-containing cosmetic composition according to this disclosure may be appropriately determined so that the specific liposomes have a single lamellar structure and an average particle size of 100 nm to 500 nm. The polyoxyethylene phytosterol content relative to the total mass of the liposome-containing cosmetic composition may be 0.00005% to 0.25% by mass, or 0.05% to 0.20% by mass.

[0037] (Cholesterol: component C) In this disclosure, cholesterol includes cholestanol and cholesterol derivatives.

[0038] Examples of cholesterol include cholesterol, dihydrocholesterol, dehydrocholesterol, cholesteryl oleate, cholesteryl isostearate, cholesteryl hydroxystearate, and polyoxyethylene cholesteryl ether.

[0039] The cholesterol content in the liposome-containing cosmetic composition may be appropriately determined so that the specific liposomes have a single lamellar structure and an average particle size of 100 nm to 500 nm. The cholesterol content relative to the total mass of the cosmetic liposome composition may be 0.003% to 0.5% by mass, or 0.1% to 0.20% by mass.

[0040] (Lecithin: D component) Examples of lecithin include natural lecithin obtained from plants such as soybeans, rapeseed, sunflower, safflower, peanuts, cottonseed, corn, rice, and barley, as well as egg yolks, and their derivatives (hereinafter also referred to as lecithin derivatives). Examples of lecithin derivatives include hydrogenated lecithin, enzymatically treated lecithin (also called lysolecithin), and compounds in which polyethylene glycol, aminoglycans, etc., are introduced into the phospholipids in lecithin. Among the above, hydrogenated lecithin is particularly preferred from the viewpoint of oxidative stability.

[0041] From the viewpoint of the long-term stability of liposome-containing compositions for cosmetics, the phosphatidylcholine content (hereinafter also referred to as PC content) relative to the total mass of lecithin is preferably 75% by mass or more, more preferably 80% by mass or more, even more preferably 85% by mass or more, and particularly preferably 90% by mass or more. The PC content can be measured by thin-layer chromatography / flame ionization detection (TLC / FID) or high-performance liquid chromatography (HPLC).

[0042] Lecithin can be purchased commercially. Examples of commercially available lecithins include COATSOME NC-21 (PC content of 90% by mass or more) manufactured by NOF Corporation, and NIKKOL® Lesinol S-10E (PC content of 75% to 85% by mass) manufactured by Nikko Chemicals Co., Ltd.

[0043] The lecithin content in the liposome-containing cosmetic composition according to this disclosure may be determined as appropriate to satisfy the preferred embodiments described above. The lecithin content relative to the total mass of the cosmetic liposome composition may be 0.01% to 1.0% by mass, or 0.5% to 0.6% by mass.

[0044] =Quantitative relationship between component A and components B, C, and D= In the liposome-containing cosmetic composition according to this disclosure, the ratio of the content of γ-aminobutyric acid (component A) to the total content of polyoxyethylene phytosterol (component B), cholesterol (component C), and lecithin (component D) (A / (B+C+D)) is preferably 0.05 to 20.0 by mass, more preferably 0.1 to 20.0, even more preferably 0.5 to 15, and even more preferably 1.0 to 13.0. When the ratio (A / (B+C+D)) is 0.1 to 20.0, the liposome-containing cosmetic composition can more stably contain fine liposomes with an average particle diameter of 500 nm or less.

[0045] (Compound E: component E, which is at least one compound selected from the group consisting of fatty acid phytosteryls and sphingoid bases) In compound E, fatty acid phytosteryl refers to an ester of a fatty acid and a phytosterol. Fatty acid phytosteryls may be esters of fatty acids having 12 to 22 carbon atoms and phytosterols. Fatty acid phytosteryls may also be esters of a mixture of fatty acids with different carbon number configurations and phytosterols. One suitable embodiment of the fatty acid phytosteryl is oleic acid phytosteryl.

[0046] In compound E, a sphingoid base refers to a long-chain aliphatic amine that is a component of sphingolipids and contains two or three hydroxyl groups at its terminus. Examples of sphingoid bases include phytosphingosine, dihydrosphingosine, sphingosine, hydroxysphingosine, and caprooylsphingosine. In one preferred embodiment, phytosphingosine is used as the sphingoid base.

[0047] In this disclosure, the specific liposome may contain only one of either a fatty acid phytosteryl or a sphingoid base as compound E, or it may contain both a fatty acid phytosteryl and a sphingoid base.

[0048] The content of compound E in the liposome-containing cosmetic composition disclosed herein is: Specific liposomes The composition may be appropriately determined to have a single lamellar structure and an average particle diameter of 100 nm to 500 nm. The content of compound E relative to the total mass of the cosmetic liposome composition may be 0.001% to 0.5% by mass, or 0.05% to 0.1% by mass.

[0049] In this disclosure, "content of compound E" means: If compound E consists solely of fatty acid phytosteryl, then it means the content of fatty acid phytosteryl. If the compound corresponding to compound E consists only of sphingoid bases, then it means the sphingoid base content. If compound E contains both fatty acid phytosteryls and sphingoid bases, it refers to the sum of the content of fatty acid phytosteryls and sphingoid bases.

[0050] =Quantitative relationship between component A and component E= In the liposome-containing cosmetic composition according to this disclosure, the ratio of the content of γ-aminobutyric acid (component A) to the content of compound E (component E) (A / E) is preferably 0.4 to 1000 by mass, more preferably 2 to 400, and even more preferably 20 to 200. When the ratio (A / E) is 0.4 to 1000, the liposome-containing cosmetic composition exhibits excellent suppression of precipitation and can more stably contain fine liposomes with an average particle diameter of 500 nm or less.

[0051] (Ergothioneine) The liposome-containing cosmetic composition relating to this disclosure may further contain ergothioneine. In this disclosure, the term ergothioneine includes ergothioneine and derivatives of ergothioneine. Ergothioneine is known as a naturally derived ingredient with antioxidant properties.

[0052] Ergothioneine is known as a compound having the following structure.

[0053] [ka]

[0054] The structures of ergothioneine derivatives are shown below.

[0055] [ka]

[0056] In the above formula, X represents -O-R' or -NR'R'', and R, R', and R'' each independently represent a hydrogen atom, a C1-C18 alkyl group, a C1-C18 alkenyl group, or a C1-C18 acyl group. The alkyl group, alkenyl group, or acyl group may form a salt. The alkyl group may be linear or branched. The alkyl group, alkenyl group, or acyl group may be substituted with a hydroxyl group, an esterified hydroxyl group, a halogen atom, a carboxyl group and its derivatives, an amine group and its derivatives, and may contain heteroatoms, such as an oxygen atom or an ionic atom, in the chain. Derivatives of ergothioneine include β-hydroxyergothioneine.

[0057] Commercially available ergothioneine can be used. Any commercially available ergothioneine commonly used in pharmaceuticals, quasi-drugs, and cosmetics is acceptable without any particular restrictions.

[0058] Ergothioneine can be extracted, for example, from mushrooms of the Pleurotaceae family. Furthermore, as ergothioneine, compounds obtained by known methods such as fermentation and chemical synthesis can also be used. Among these, ergothioneine extracted from mushrooms is preferred from the viewpoint of being derived from natural products and having a high yield.

[0059] Commercially available ergothioneine products include powders sold as ergothioneine, or compositions containing pre-dissolved ergothioneine. Examples of commercially available products include L-Ergothioneine from Asahi Trading Co., Ltd., AntiOxd-Ex from Shenzhen Readline Biotech Co., Ltd., Bioyout®-EGT Pure ultra-high purity ergothioneine from BLOOMAGE BIOTECHNOLOGY Corp., Ltd., THIOTAINE from AGI Dermatics, and Natural ERG Liquid from Koei Kogyo Co., Ltd.

[0060] The liposome-containing cosmetic composition relating to this disclosure may contain only one compound included in ergothioneine, or it may contain two or more compounds.

[0061] In the liposome-containing cosmetic composition according to this disclosure, there are no particular restrictions on the ergothioneine content, and it can be appropriately selected depending on the purpose. In particular, from the viewpoint of obtaining sufficient antioxidant effect, the ergothioneine content is preferably 0.0001% to 1% by mass on a mass basis, relative to the total mass of the liposome-containing cosmetic composition.

[0062] (water) The liposome-containing cosmetic composition relating to this disclosure contains water. Water is included in the liposome-containing cosmetic composition as one of the components contained within the liposome encapsulation, and as one of the components constituting the dispersion medium for dispersing the liposomes in the composition. Examples of water, which is one of the inclusions, and the water contained in the dispersion medium include ion-exchanged water, pure water, purified water, and tap water, and among these, purified water is preferred due to its applicability to cosmetics.

[0063] The water content relative to the total mass of the liposome-containing composition for cosmetics is not particularly limited, but is preferably 1% to 99% by mass, more preferably 10% to 95% by mass, and even more preferably 20% to 90% by mass. In this disclosure, "water content relative to the total mass of the liposome-containing composition for cosmetics" means the sum of the water content encapsulated in the liposomes and the water content in the dispersion medium relative to the total mass of the liposome-containing composition for cosmetics.

[0064] (ethanol) The liposome-containing cosmetic composition relating to this disclosure preferably contains ethanol from the viewpoint of facilitating the production of liposomes. Ethanol may be contained within the liposome encapsulation (i.e., encapsulated within the liposome), contained in the dispersion medium, or contained in both the encapsulation and the dispersion medium. Either ethanol or anhydrous ethanol, whichever is available, can be used as the ethanol.

[0065] From the viewpoint of the long-term stability of liposomes, the ethanol content relative to the total mass of the liposome-containing composition for cosmetics is preferably 0.2% to 30% by mass. Furthermore, the ethanol content relative to the total mass of the liposome-containing composition for cosmetics may be 1% by mass or more, 3% by mass or more, or 5% by mass or more. Furthermore, the ethanol content relative to the total mass of the liposome-containing composition for cosmetics may be 25% by mass or less, 20% by mass or less, or 15% by mass or less. In this disclosure, "ethanol content relative to the total mass of the liposome-containing composition for cosmetics" means the sum of the ethanol content encapsulated in the liposomes and the ethanol content contained in the dispersion medium, relative to the total mass of the liposome-containing composition for cosmetics.

[0066] (Beauty ingredients) In this disclosure, "beauty ingredient" means an ingredient that acts on the body, such as the skin, and can produce a beauty effect, and refers to an active ingredient used in cosmetics, etc. The aforementioned gamma-aminobutyric acid (component A) and ergothioneine can function as beauty ingredients.

[0067] The liposome-containing cosmetic composition relating to this disclosure may contain other cosmetic ingredients besides γ-aminobutyric acid (component A) and ergothioneine. These other cosmetic ingredients may be encapsulated inside the liposome (internal aqueous phase) or contained outside the liposome (external aqueous phase).

[0068] Other cosmetic ingredients that can be used include those used in the field of cosmetics (i.e., cosmetics and quasi-drugs (e.g., medicated cosmetics)).

[0069] Specifically, the beauty ingredients include tranexamic acid, Sanguisorba officinalis extract, ascorbic acid, ascorbic acid stearate, sodium ascorbate disodium ascorbic acid sulfate, aspartic acid, aspartame, acetylglucosamine, acetylglutamic acid, acetylcysteine, acetylpantothenyl ethyl ester, adenosine triphosphate disodium, adenosine monophosphate disodium, ε-aminocaproic acid, allantoin, allantoin-β-glycyrrhetinic acid, albumin, and ino. Sit, erythritol, glucosamine hydrochloride, pyridoxine hydrochloride, oxyproline, orotic acid, hydrolyzed elastin, caffeine hydrate, chondroitin sulfate sodium, cyanocobalamin, water-soluble elastin, taurine, palmitoyl methyl taurate sodium, myristoyl methyl taurate sodium, thiamine hydrochloride, theanine, deoxyribonucleic acid, ascorbyl palmitate, pantothenyl alcohol, sodium pantothenate, calcium pantothenate, pyridoxine, phytic acid, placenta extract Flavin adenine dinucleotide disodium dihydrate, anhydrous caffeine, riboflavin, riboflavin butyrate, riboflavin phosphate, resorcinol, levulinic acid, glycine, arginine, lysine solution, lauroyl lysine, palmitoyl aspartate, cysteine, methionine, glutamic acid, threonine, serine, tyrosine, histidine, proline, glutathione, salicylic acid, nicotinamide, retinyl palmitate, alginic acid, γ-undecalactone, perilla oil, estradiol, es Examples include thorone, ergocalciferol, β-carotene, glucosamine, cholecalciferol, tocopherol acetate, retinol acetate, shikonin, ascorbyl dipalmitate, pyridoxine dipalmitate, natural vitamin E, α-tocopherol, horse oil, γ-nonalactone, bisabolol, vitamin A oil, hinokitiol, fumaric acid, powdered vitamin A, tocopherol linoleate, δ-tocopherol, isoleucine, phenylalanine, valine, leucine, and ascorbyl tetra-2-hexyldecanoate. Note that caffeine includes anhydrous caffeine.

[0070] From the viewpoint of solubility in liposome encapsulation and dispersion media, other cosmetic ingredients are preferably water-soluble among those mentioned above. The types and amounts of other beauty ingredients should be set appropriately according to the purpose.

[0071] (Other ingredients) The liposome-containing cosmetic composition relating to this disclosure may also contain other ingredients such as physiological saline, sugar, pH adjusters, and preservatives. Examples of sugars include glucose, fructose, lactose, sucrose, trehalose, lactulose, and maltitol. Examples of pH adjusters include sodium hydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate anhydrous, sodium hydroxide (caustic soda), citric acid, acetic acid, and triethanolamine. Examples of preservatives include methyl parahydroxybenzoate.

[0072] The pH of the liposome encapsulation and dispersion medium is not particularly limited, but is preferably 5 to 9, and more preferably 7 to 8. The pH of the encapsulation and dispersion medium can be adjusted using the pH adjusting agent described above.

[0073] [Manufacturing method] The method for producing the liposome-containing composition for cosmetics related to this disclosure is described below, but is not limited thereto. The liposome-containing cosmetic composition according to this disclosure can be manufactured by preparing an oil phase composition and an aqueous phase composition, mixing the obtained oil phase composition and aqueous phase composition, stirring and emulsifying them to form liposomes.

[0074] By mixing, stirring, and emulsifying the oil phase composition and the aqueous phase composition, the oil phase composition and the aqueous phase composition are emulsified into an O / W type (oil-in-water type), and a liposome-containing composition for cosmetics according to the present disclosure, which includes liposomes and a dispersion medium, is produced.

[0075] Ultrasonic waves or mechanical shear force are used as stirring methods. Furthermore, to ensure uniform particle size, extruder treatment or microfluidizer treatment using a filter with a fixed pore size can be performed. By performing extruder treatment or similar procedures, multi-celled liposomes containing multiple unicellular liposomes can be separated into multiple unicellular liposomes.

[0076] The liquid temperature of the mixture can be adjusted as appropriate, but it is preferable to set it to a temperature higher than the phase transition temperature of the lecithin contained in the mixture, for example, it is preferable to set it to 35°C to 70°C.

[0077] In the production of the liposome-containing cosmetic composition according to this disclosure, the organic solvent and water may be evaporated from the composition after the liposomes have been formed (i.e., the composition containing the liposomes). The above evaporation includes both intentionally evaporating some or all of the organic solvent and water, and the spontaneous evaporation of some or all of the organic solvent and water during the stirring and emulsification process.

[0078] When intentionally evaporating organic solvents and water, the evaporation method is not particularly limited, but examples include heating the organic solvents and water, letting the cosmetic liposome-containing composition stand, stirring the cosmetic liposome-containing composition, and vacuum degassing.

[0079] The method for encapsulating substances (e.g., cosmetic ingredients) into liposomes is not particularly limited and can be carried out by using an aqueous phase composition in which the cosmetic ingredients are dissolved during emulsification.

[0080] The obtained cosmetic liposome-containing composition may be subjected to dialysis, filtration, extrusion, etc., and these methods can make the average particle size of the contained liposomes uniform. Extrusion is a method of micronizing the cosmetic liposome-containing composition by applying physical shear force by passing it through a filter having pores. The composition and filter can be rapidly atomized by keeping them at a temperature above the phase transition temperature of lecithin.

[0081] Cosmetics The cosmetic composition relating to this disclosure is made using the liposome-containing composition for cosmetic composition relating to this disclosure as described above. The cosmetic composition relating to this disclosure may include, as a part, the liposome-containing composition for cosmetic use relating to this disclosure, or may consist entirely of the liposome-containing composition for cosmetic use relating to this disclosure. In other words, the liposome-containing composition for cosmetic use relating to this disclosure may be used as a cosmetic composition as is. If the cosmetic composition relating to this disclosure includes, as a part thereof, the amount of the liposome-containing composition for cosmetic purposes relating to this disclosure may be, for example, 0.1% to 10% by mass or 1% to 2% by mass, based on the total mass of the cosmetic composition relating to this disclosure.

[0082] The form of the cosmetic composition relating to this disclosure is not particularly limited and may be a liquid, a jelly, a gel, a cream, a solid such as a stick, or a semi-solid. The uses of the cosmetics related to this disclosure include, but are not limited to, skincare cosmetics (lotions, emulsions, serums, sunscreens, face masks, etc.), body cosmetics (body lotions, body sunscreens, etc.), and scalp cosmetics. Depending on the form, use, etc., the cosmetic composition relating to this disclosure may contain components other than the liposome-containing composition for cosmetic composition relating to this disclosure. [Examples]

[0083] The above embodiments will be described in detail below with reference to examples, but the above embodiments are not limited to these examples.

[0084] <Example 1> (Preparation of oil phase composition) Polyoxyethylene phytosterol (average number of moles of oxyethylene groups added: 20), hydrogenated lecithin (hydrogenated soybean phospholipid, PC content 90% or more), cholesterol, tetra-2-hexyldecanoate ascorbyl, phytosteryl oleate, and anhydrous ethanol were mixed and dissolved by heating at 60°C for 10 minutes to obtain oil phase composition X.

[0085] (Preparation of aqueous phase composition) Anhydrous disodium hydrogen phosphate, sodium dihydrogen phosphate, γ-aminobutyric acid, and purified water were mixed and heated at 60°C for 10 minutes to dissolve and obtain aqueous phase composition Y-1. Furthermore, methyl parahydroxybenzoate and purified water were mixed and heated at 60°C for 10 minutes to dissolve them and obtain aqueous phase composition Y-2.

[0086] (Manufacturing of liposome-containing compositions for cosmetics) The aqueous phase composition Y-1 obtained above was stirred in a homomixer at 3400 rpm (revolutions per minute) while maintaining the temperature at 60°C, and then the oil phase composition X was added to the aqueous phase composition Y-1. After addition, the mixture of aqueous phase composition Y-1 and oil phase composition X was stirred at 3400 rpm for 45 minutes. Aqueous phase composition Y-2 was added to the stirred mixture and uniformly stirred for 5 minutes, after which it was cooled to below 5°C for 35 minutes. After cooling, it was filtered through a 230-mesh filter cloth. Through this process, a cosmetic composition (liposome-containing cosmetic composition) was obtained. The content of each component in the cosmetic composition (liposome-containing cosmetic composition) was as shown in Table 1.

[0087] <Examples 2 to 9> A cosmetic composition (liposome-containing cosmetic composition) was prepared in the same manner as in Example 1, except that the composition of the cosmetic composition was changed as shown in Table 1.

[0088] <Comparative Example 1 to Comparative Example 15> A cosmetic composition (liposome-containing cosmetic composition) was prepared in the same manner as in Example 1, except that the composition of the cosmetic composition was changed as shown in Table 2.

[0089] [evaluation] The cosmetic compositions produced in each example were evaluated as shown in Evaluation 1 and Evaluation 2 below. Cosmetic compositions that excel in both Evaluation 1 and Evaluation 2 are determined to be cosmetic compositions that contain γ-aminobutyric acid and stably contain fine liposomes having a single lamellar structure.

[0090] <<Evaluation 1: Monolayer ratio (percentage of liposomes with a single lamellar structure)>> Liposomes contained in the cosmetic compositions manufactured in each example were embedded in ice, and TEM images at a magnification of 50,000x were obtained using a transmission electron microscope.

[0091] The average ratio of liposomes with a single lamellar structure to the total number of liposomes in a liposome-containing cosmetic composition was determined by counting the total number of liposomes with a single lamellar structure and the total number of liposomes with a single lamellar structure within a circle with a radius of 2 μm at three randomly selected locations from the TEM image, and evaluated based on the following evaluation criteria. A higher monolayer ratio (percentage of liposomes with a single lamellar structure) is preferable, specifically, ranks "A" and "B" are preferred, with "A" being the most preferred rank. (Evaluation Criteria) A: The percentage of single-story buildings was 70% or higher. B: The percentage of single-story buildings was between 50% and 70%. C: The single-layer ratio was between 30% and 50%. D: The single-layer ratio was greater than 0% but less than 30%. E: The monolayer ratio was 0% (no liposomes with a single lamellar structure were observed).

[0092] <<Evaluation 2: Average particle size of liposomes>> The cosmetic compositions prepared in each example were diluted 10 times by mass with pure water, and the volume-average particle size of the liposomes contained was measured by dynamic light scattering using a concentrated particle size analyzer FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.). The volume-average particle size was measured within 20 to 24 hours after the preparation of the cosmetic composition. The measurement environment temperature was set to 25°C. The obtained average particle size measurements were evaluated based on the following evaluation criteria. The measured and evaluated average particle size of liposomes are shown in Table 1 or Table 2. The average particle size of the liposomes must be of rank "A" or "B," with "A" being the most preferred rank. (Evaluation Criteria) A: The average particle size was between 100 nm and 300 nm. B: The average particle diameter was between 300 nm and 500 nm. C: The average particle diameter was greater than 500 nm but less than 7000 nm. D: The average particle diameter was less than 100 nm or greater than 700 nm.

[0093] Tables 1 and 2 below show the composition of the cosmetic compositions produced in each example, as well as the evaluation results. In Tables 1 and 2, blank spaces in the composition column indicate that the corresponding component is not present. In Tables 1 and 2, "A / (B+C+D)" represents the ratio of γ-aminobutyric acid content to the total content of polyoxyethylene phytosterols, cholesterol, and lecithin. In Table 1, "A / E" indicates the ratio of γ-aminobutyric acid content to compound E content. In Table 2, "-" in the "A / E" column indicates that the cosmetic composition does not contain compound E, and therefore "A / E" cannot be calculated. In Table 2, the "-" in the single-layer ratio column indicates that the average particle diameter clearly exceeds 500 nm, and therefore "Evaluation 1: Single-layer Ratio" was not performed.

[0094] [Table 1]

[0095] [Table 2]

[0096] As shown in Table 1, it was confirmed that all cosmetic compositions of Examples 1 to 9 are cosmetic compositions that stably contain fine liposomes having an average particle size of 100 nm to 500 nm, a monolayer ratio of rank A or B, γ-aminobutyric acid, and a single lamellar structure.

[0097] As shown in Table 2, Comparative Examples 1, 8-15 (which did not contain compound E), Comparative Examples 2 and 3 (which used stearic acid instead of compound E), and Comparative Example 4 (which used stearyl alcohol instead of compound E) were all cosmetic compositions containing liposomes with an average particle size exceeding 700 nm. Furthermore, as shown in Table 2, Comparative Examples 5, which used oleic acid instead of compound E, and Comparative Examples 6 and 7, which used isostearic acid instead of compound E, all contained liposomes with an average particle size of less than 100 nm and also had a low monolayer ratio.

[0098] The details of the components shown in Tables 1 and 2 are as follows:

[0099] (Oil phase composition) • Polyoxyethylene phytosterol (product name: Nikkol® BPS-20, Nikko Chemicals Co., Ltd., component B) • Cholesterol (Product name: Cholesterol JSQI, Nippon Seika Co., Ltd., component C) • Hydrogenated lecithin (hydrogenated soybean phospholipid, PC content 90% or more, D component) • Phytosphingosine (Trade name: Phytosphingosine, Evonik, component E) • Stearic acid (product name: Lunac S-98, Kao Corporation, comparative compound of component E) • Stearyl alcohol (Product name: Stearyl Alcohol NX, manufactured by Higher Alcohol Industry Co., Ltd., comparative compound of component E) • Oleic acid (product name: Lunac OV, Kao Corporation, comparative compound of component E) • Isostearic acid (product name: Isostearic acid EX, manufactured by Higher Alcohol Industry Co., Ltd., comparative compound of component E) • Tetra-2-hexyldecanoate ascorbyl (Nikkol® VC-IP, Nikko Chemicals Co., Ltd., and other beauty ingredients)

[0100] (Aqueous phase composition) • Gamma-aminobutyric acid (product name: Gabacare) TM BL98T Aminobutyric acid, BLOOMAGE BIOTECHNOLOGY Corp., Ltd., A component) • Ergothioneine raw material (product name: Natural_ERG_Liquid, Koei Kogyo Co., Ltd., ergothioneine concentration: 0.03% by mass) ·Water (purified water)

Claims

1. This is a liposome-containing composition for cosmetics that contains liposomes and water. A liposome-containing composition for cosmetics, wherein the liposomes comprise γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, and compound E, which is at least one selected from the group consisting of fatty acid phytosteryls and sphingoid bases, and the liposomes have a single lamellar structure and an average particle diameter of 100 nm to 500 nm.

2. The liposome-containing cosmetic composition according to claim 1, wherein the ratio of the content of γ-aminobutyric acid to the content of compound E is 0.4 to 1000 by mass.

3. A liposome-containing cosmetic composition according to claim 1 or claim 2, wherein the ratio of the content of γ-aminobutyric acid to the total content of polyoxyethylene phytosterol, cholesterol, and lecithin is 0.05 to 20.0 by mass.

4. Furthermore, the liposome-containing cosmetic composition according to claim 1 or claim 2, further comprising ergothioneine.

5. A cosmetic product comprising the liposome-containing composition for cosmetics described in claim 1.

Images